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Introduction: Uric acid was proposed to have anti-oxidant property and possible neuroprotective effects. We
examined the association between gout and dementia with population database.
Methods: The study utilized the claims data from the nationwide representative sample of Taiwan National Health
Insurance Research Database (NHIRD). We ascertained patients with gout and dementia covering vascular and
non-vascular (including Alzheimer’s) subtypes using International Classification of Diseases Ninth Revision, Clinical
Modification (ICD9-CM) codes. A control group matched on sex, age, and index date of gout patients was randomly
sampled with a ratio of 1:4 from the same database for comparison.
Results: From 2002 to 2008, 28,769 gout patients who were older than 50 years old were identified, and 114,742
control patients was matched into the study. During follow-up, 7,119 patients developed dementia (1,214 with
gout, and 5,905 without gout). After adjusting for age, sex, and relevant comorbidities, a Cox regression analysis
showed that gout patients had a lower risk of developing non-vascular dementia (hazard ratio (HR): 0.77; 95%
confidence interval (CI): 0.72 - 0.83; p < 0.001) and vascular dementia (HR: 0.76; 95% CI: 0.65 - 0.88; p < 0.001).
Conclusions: Patients with gout have a lower risk of developing dementia. This phenomenon exists for both
non-vascular and vascular types of dementia.Introduction
Dementia is one of the most commonly seen neuro-
logical diseases that have significant impact on public
health. There are several types of dementia among which
Alzheimer’s disease and vascular dementia are the two
major types [1]. Vascular dementia has a strong associ-
ation with stroke and metabolic syndrome. Recent stud-
ies also revealed association between Alzheimer’s disease
and metabolic syndrome [2,3]. As gout and hyperuricemia
are related to metabolic syndrome and cardiovascular dis-
eases, this raises the question of whether patients with
gout having higher risk of dementia [4]. However, it has
long been proposed that uric acid has possible neuropro-
tective effects [5-7]. Some studies revealed that patients
with gout have lower risks of developing Parkinson’s dis-
ease [8,9].A similar neuroprotective effect of uric acid has
been found in animal models of multiple sclerosis [5]. It is* Correspondence: hylin@vghtpe.gov.tw
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stated.still unclear whether uric acid has a protective effect in
other neurologic degenerative diseases, such as demen-
tia. Some more recent studies reveal that patients with
Alzheimer’s disease tend to have lower central nervous
system (CNS) uric acid levels [10], and higher serum urate
level is associated with a reduced rate of cognitive decline
in patients with mild cognitive impairment [11]. A cohort
study by Euser et al. also demonstrated that higher uric
acid levels are related to a decreased risk of dementia [12].
To determine the clinical implications of these findings,
we examined the relationship between gout and dementia
by analyzing a large population-based database.Methods
The study was approved by the Institutional Review
Board of Taipei Veteran’s General Hospital (approval
number: 2013-11-001CE). Informed consent of the study
participants was not required because the dataset used
in this study consists of de-identified secondary data
released for research purposes.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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In Taiwan, the national health insurance (NHI) program
launched in 1995 provides a universal and comprehen-
sive health care system for all citizens. Registration to
the NHI is obligatory for every citizen and hence its
coverage rate is nearly 100%. The NHI program covers
outpatient services, inpatient care, emergency medicine,
Chinese medicine, dental care, and all other medically
necessary services. Those who cannot afford the pre-
mium are subsidized so they can still be enroled. The
NHI database contains the original claims data, includ-
ing demographic information, and information on diag-
nosis, examinations, drug prescriptions, and operations.
The National Health Research Institutes acquired the
original claims data for reimbursement from the
Administration of National Health Insurance, Taiwan.
After de-identification and some encryption processing,
the data were released under the name of National
Health Insurance Research Database (NHIRD) for re-
search purposes. In addition, for ease of research and
computing, NHIRD also provides a set of sampling files
named the Longitudinal Health Insurance Database
(LHID). In our study we used LHID 2005, which con-
tains the original claims data of 1,000,000 beneficiaries
randomly sampled from the entire population in 2005.
During 2005 to 2006, there were about 25.68 million
individuals in the whole NHI registry. There was no
significant difference in the gender distribution, age
distribution, or average insured payroll-related amount
between the patients in the LHID 2005 and the original
NHIRD (χ2 = 0.008, degrees of freedom (df ) = 1,
P-value = 0.931) [13]. The PostgreSQL Global Develop-
ment Group (PostgreSQL) version 9.2 was adopted to
manage the database. We also employed computer
programs in structured query language (SQL) for initial
data processing and sample selection.
Ascertainment of gout
In the NHIRD, all diagnoses are documented using
International Classification of Diseases Ninth Revision,
Clinical Modification (ICD9-CM) codes. For the defin-
ition of gout cases, we used methods validated in the
previous studies [14,15]. A patient was considered to
have gout if he or she had ICD9-CM code 274 docu-
mented more than twice across outpatient visits. To
ensure the accuracy of this definition, we carried out a
sensitivity analysis. We tried to estimate the percentage
of the people with gout who were receiving at least one
prescription of medication for treatment of gout, including
colchicine, allopurinol, benzbromarone, sulfinpyrazone,
and probenecid. Seventy-five percent of the patients were
prescribed at least one anti-gout drug; this ratio is very
close to the numbers reported by other studies, suggesting
that the inclusion of gout was valid [8]. As dementia ismainly a disease of the elderly, individuals younger than
50 years at the time of first gout diagnosis were excluded
from the study. In our cohort, the incidence rates of gout
per 1,000 person-years were 6.6 cases among male pa-
tients and 2.2 cases among female patients respectively.
The values are nearly identical to that reported in other
studies [8].
Sampling of comparison group
Up to four controls without gout, matched by age, sex,
and index date for each gout case were randomly chosen
from the same cohort. For each gout patient, we defined
the date of the first recorded gout diagnosis as the index
date. We then searched in the database for all age- and
sex-matched controls who did not have gout on the pa-
tient’s index date. Next, we randomly sampled up to four
controls for each individual from all eligible controls.
The same procedure was performed repeatedly until all
of them had found matched controls. During each iter-
ation, controls that had already been selected previously
were excluded. The baseline characteristics of the gout
patients and their controls were based on the status on
their index dates. Patients with gout for whom no
matched controls could be found were excluded from
the study. The recruitment process of the patients and
their comparison group is summarized in Figure 1.
Outcome measurement and ascertainment of dementia
Our primary outcome was the first recorded diagnosis of
any type of dementia. The ascertainment of dementia
was done by searching for ICD9-CM code 331.0 and
290.0-290.4 recorded in the claims. We further exam-
ined different subtypes of dementia. The patients with
ICD9-CM code 290.4 series recorded in the claims were
classified as having vascular dementia. All remaining de-
mentia patients who did not belong to the vascular de-
mentia group were defined as having non-vascular
dementia. We also differentiated patients with Alzheimer’s
disease from those with non-vascular dementia by search-
ing for ICD9-CM code 331.0. With these definitions, the
incidence density of dementia from the NHIRD during our
study period was calculated as 2.02 per 1,000 person-years.
All patients having dementia prior to the beginning of gout
exposure or their index dates were excluded. The end of
the study was 31 December 2008. Censoring was defined as
death or the end of the study, whichever came first.
Covariate assessment
For the ICD-9 CM codes used to ascertain other rele-
vant comorbidities, we included diabetes mellitus (250),
hyperlipidemia (272), heart failure (428), hypertension
(401-405), coronary artery disease (410-414), chronic ob-
structive pulmonary disease (490-496), asthma (493.), ische-
mic stroke (433, 434, 436, 437.1), malignancy (140.0-208),
Figure 1 Flowchart of the included study sample. Among the included patients who had fewer than four controls, 80 patients had only one
matched control, 45 patients had 2 controls, and 44 patients had 3 controls.
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785.1), and Parkinson’s disease (332). These comorbidities
were tested in the univariate analysis and were adjusted for
in the multivariate Cox regression analysis.Statistical analysis
The statistical analysis was conducted using SPSS Statis-
tics version 20 (International Business Machines Corp.,
New York, NY, USA). In each group, patients’ data were
described by frequencies and percentages for categorical
variables, and by mean ± standard deviation for continu-
ous variables. Categorical variables were compared using
the chi-square test or Fisher’s exact test. Continuous vari-
ables were compared using the independent t-test. The
Cox-proportional hazard model was used to estimate the
relative risk of developing dementia in the adjusted ana-
lysis. Hazard ratios and 95% confidence intervals were
computed. A two-tailed P-value <0.05 was considered sta-
tistically significant. To validate our results and avoid the
potential bias from coding errors in dementia diagnosis,
we conducted a sensitivity analysis by running the Cox re-
gression test with a more strict definition of Alzheimer’s
disease. The definition required not only ICD9-CM code
331.0 but also any documented prescriptions of medica-
tions used to treat Alzheimer’s disease, including donepe-
zil, rivastigmine, galantamine, and memantine.Results
From 2002 to 2008, we ascertained 30,316 patients aged
50 years and over with first record of gout and no his-
tory of dementia. Of the gout patients 1,537 (5.1%) had
no matched controls and were excluded. All of the
excluded patients were male. The average age of the
excluded patients was 68.8 ± 5.6 years, which is higher
than the average age of the included patients (63.5 ± 9.7).
Finally, 28,769 gout patients and 114,742 controls were
enroled into the study. In the groups with and without
gout, most of the patients were male (63.6% and 63.4%)
and the average age was 63.5 ± 9.7 years in both groups.
Compared with the non-gout group, individuals with gout
had a higher frequency of comorbid medical conditions,
including hypertension, hyperlipidemia, diabetes mellitus,
coronary artery disease, heart failure, arrhythmia, chronic
obstructive pulmonary disease, asthma, previous history of
stroke, and chronic kidney disease. The mean follow-up
duration was 4.3 ± 2.1 years for the gout cases and 4.4 ±
2.0 for the non-gout controls for all types of dementia.
During the follow-up period, we identified 6,848 new cases
of dementia (1,214 in the gout group and 5,634 in the non-
gout group). The incidence of dementia in the gout and
non-gout groups was 9.51 per 1000 person-years and 12.54
per 1000-person years, respectively. Detailed baseline char-
acteristics and follow-up information on different dementia
subtypes can be seen in Table 1.
Table 1 Baseline characteristics and follow-up information







Age 63.5 ± 9.7 63.5 ± 9.7 0.979
Male 72,642 (63.3%) 18,254 (63.4%) 0.724
Hypertension 38,947 (33.9%) 15,613 (54.3%) <0.001
Hyperlipidemia 11,177 (9.7%) 6,566 (22.8%) <0.001
Diabetes mellitus 18,968 (16.5%) 6,504 (22.6%) <0.001
Coronary artery disease 16,937 (14.8%) 6,146 (21.4%) <0.001
Heart failure 3,604 (3.1%) 1,533 (5.3%) <0.001
Arrhythmia 11,678 (10.2%) 3,800 (13.2%) <0.001
Chronic obstructive
pulmonary disease
21,789 (19.0%) 6,590 (22.9%) <0.001
Asthma 7,892 (6.9%) 2,698 (9.4%) <0.001
Stroke 5,771 (5.0%) 1,611 (5.6%) <0.001
Malignancy 5,484 (4.8%) 1,337 (4.6%) 0.341
Chronic kidney disease 5,128 (4.5%) 2,479 (8.6%) <0.001
Parkinson's disease 1,296 (1.1%) 290 (1.0%) 0.077
Follow-up information
All dementia types
Follow-up duration 4.3 ± 2.1 4.4 ± 2.0 <0.001
New cases
(incidence density)
5,905 (11.9) 1,214 (9.5)
Vascular dementia
Follow-up duration 4.4 ± 2.0 4.5 ± 2.0 <0.001
New cases
(incidence density)
991 (2.0) 210 (1.6)
Non-vascular dementia
Follow-up duration 4.3 ± 2.0 4.5 ± 2.0 <0.001
New cases
(incidence density)
4,914 (9.9) 1,004 (7.8)
Alzheimer's disease
Follow-up duration 4.4 ± 2.0 4.5 ± 2.0 <0.001
New cases
(incidence density)
542 (1.1) 102 (0.8)
Follow-up duration is expressed in person-years. Incidence density values are
per 1000-person-years.
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groups, both unadjusted univariate and adjusted multi-
variate Cox regression analysis were carried out. The re-
sults are summarized in Table 2. After adjusting for age,
sex, and relevant comorbidities, patients with gout had a
lower risk of developing dementia compared with the
control group (hazard ratio (HR): 0.77, 95% CI: 0.72,
0.82, P <0.001). As dementia patients as a whole repre-
sent a heterogeneous group of various pathogeneses and
clinical courses, we conducted a secondary analysis to
estimate the risks of vascular and non-vascular dementiaseparately. The results are shown in Table 2. Among the
dementia events, 1,154 were due to vascular dementia, and
5,694 due to non-vascular dementia. The patients with gout
had lower risks of both vascular and non-vascular demen-
tia. In the sensitivity analysis, gout patient still had lower
risk of Alzheimer’s disease (HR: 0.76; 95% CI: 0.61, 0.95;
P = 0.014), which remained consistent with our secondary
analysis of non-vascular dementia.
Discussion
The risks factors of Alzheimer’s disease and vascular de-
mentia are both similar to those of cardiovascular diseases
and cerebrovascular diseases, including hypertension
and diabetes mellitus [16-18]. Given the fact that gout and
hyperuricemia are both associated with cardiovascular
diseases [4,19], it is more natural to postulate that gout
might have positive correlation with dementia. However,
the results from earlier studies with smaller samples and
our population-based study all showed just the opposite
direction [7,11]. This finding might support the possible
neuroprotective effect of uric acid.
In our multivariate analysis, we also found that patients
with older age, diabetes mellitus, stroke, chronic kidney
disease, and Parkinson’s disease had significantly higher
risks of dementia after adjusting for covariates. These re-
sults are consistent with existing literature as these factors
are all known to be potential risk factors for dementia
[16-18,20,21]. Some authors also propose that heart fail-
ure, hypertension, coronary artery disease, chronic ob-
structive pulmonary disease, asthma, and arrhythmia are
associated with dementia, but there are also conflicting re-
ports [18,22,23]. In our study, however, these factors were
only associated with increased risks of dementia in univar-
iate analysis. These differences might reflect the hetero-
geneity in study populations, study designs and outcome
measurements. After adjustment for those confounding
factors, we still found that the risk of dementia was about
25% lower in the group with gout.
Current understanding of the pathogenesis of Alzheimer’s
disease is still limited, but evidence from existing studies
has shown that the development of the disease is related to
oxidative stress and deposition of β-amyloid [24]. Uric acid
can act as an antioxidant and reduce oxidative stress
[5,6,25]. It is a strong peroxynitrite (ONOO−) scavenger. A
human study by Waring et al. also showed significant in-
crease in serum free-radical scavenging capacity from base-
line during uric acid infusion [26]. This might partly
explain the potential neuroprotective effect. Besides, several
hypotheses were proposed to explain the development of
Alzheimer’s disease, including the amyloid cascade hypoth-
esis and mitochondrial cascade hypothesis [27]. The amyl-
oid cascade hypothesis assumes that Alzheimer’s disease is
a primary amyloidosis originated from altered processing of
amyloid precursor protein (APP) which drives production
Table 2 Cox regression analysis results for gout and covariates on dementia
Alzheimer's disease Vascular dementia Non-vascular dementia All kinds of dementia
Hazard ratio (95% CI)
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
Gout 0.74** (0.60, 0.91) 0.75* (0.61, 0.94) 0.83* (0.71, 0.96) 0.76** (0.65, 0.88) 0.79** (0.74, 0.85) 0.77** (0.72, 0.83) 0.79** (0.75, 0.85) 0.77** (0.72, 0.82)
Untreated gout 0.88 (0.62, 1.24) 0.89 (0.62,1.27) 0.92 (0.71, 1.19) 0.88 (0.86, 1.11) 0.97 (0.87, 1.09) 0.95 (0.85, 1.07) 0.96 (0.87, 1.07) 0.963 (0.84, 1.03)
Treated gout 0.67** (0.52, 0.88) 0.68** (0.52, 0.89) 0.79* (0.66, 0.95) 0.73** (0.60,0.88) 0.71** (0.65, 0.78) 0.69** (0.68, 0.75) 0.72** (0.67, 0.78) 0.69** (0.64, 0.75)
Other covariates
Age 1.11** (1.10, 1.12) 1.11** (1.10, 1.12) 1.11** (1.10, 1.11) 1.10** (1.09, 1.10) 1.12** (1.11, 1.12) 1.11** (1.11, 1.12) 1.12** (1.11, 1.12) 1.11** (1.11, 1.11)
Male sex 0.75** (0.64, 0.88) 0.84* (0.71, 0.98) 1.11 (0.98, 1.25) 1.27** (1.13, 1.44) 0.86** (0.81, 0.90) 0.94* (0.89, 0.99) 0.89** (0.85, 0.94) 0.99 (0.94, 1.04)
Diabetes mellitus 1.29* (1.06, 1.58) 1.18 (0.96, 1.46) 1.87** (1.64, 2.13) 1.45** (1.26, 1.67) 1.50** (1.41, 1.59) 1.30** (1.23, 1.40) 1.56** (1.47, 1.65) 1.33** (1.25, 1.40)
Hypertension 1.44** (1.23, 1.69) 0.93 (0.78, 1.11) 2.30** (2.05, 2.57) 1.33** (1.16, 1.51) 1.67** (1.58, 1.75) 0.99 (0.93, 1.04) 1.76** (1.68, 1.84) 1.03 (0.98, 1.09)
Hyperlipidemia 0.93 (0.71, 1.20) 0.98 (0.74, 1.29) 1.15 (0.96, 1.37) 0.98 (0.81, 1.18) 0.91* (0.84, 1.00) 0.89* (0.81, 0.97) 0.94 (0.87, 1.02) 0.90* (0.83, 0.97)
Heart failure 1.56* (1.04, 2.33) 0.79 (0.52, 1.20) 2.50** (1.97, 3.18) 1.13 (0.88, 1.45) 2.17** (1.93, 2.42) 0.98 (0.87, 1.10) 2.22** (2.00, 2.45) 1.00 (0.90, 1.12)
Coronary artery disease 1.64** (1.35, 2.00) 1.10 (0.88, 1.37) 2.05** (1.80, 2.35) 1.11 (0.96, 1.30) 1.74** (1.63, 1.86) 0.99 (0.92, 1.07) 1.79** (1.68, 1.89) 1.04 (0.97, 1.10)
COPD 1.10 (0.90, 1.36) 0.67* (0.50, 0.87) 1..43** (1.24, 1.65) 0.82* (0.69, 0.98) 1.60** (1.50, 1.70) 1.02 (0.95, 1.10) 1.55** (1.47, 1.64) 0.97 (0.90, 1.04)
Asthma 1.28 (0.94, 1.73) 1.32 (0.90, 1.95) 1.32 (1.06, 1.65) 1.01 (0.78, 1.32) 1.44** (1.31, 1.59) 0.98 (0.88, 1.10) 1.41** (1.29, 1.54) 0.99 (0.89, 1.10)
Stroke 2.10** (1.6, 2.80) 1.16 (0.86, 1.57) 6.05** (5.24, 7.00) 2.98** (2.55, 3.49) 3.09** (2.85, 3.35) 1.55** (1.42, 1.69) 3.59** (3.234, 3.86) 1.80** (1.67, 1.95)
Malignancy 1.55* (1.09, 2.19) 1.18 (0.83, 1.67) 1.26 (0.96, 1.67) 0.85 (0.64, 1.12) 1.45** (1.29, 1.63) 1.00 (0.89, 1.13) 1.41** (1.27, 1.57) 0.96 (0.87, 1.07)
Chronic kidney disease 0.93 (0.62, 1.41) 0.73 (0.49, 1.11) 1.44** (1.13, 1.85) 0.95 (0.73, 1.22) 1.61** (1.45, 1.79) 1.17** (1.05, 1.30) 1.53** (1.43, 1.73) 1.12* (1.01, 1.23)
Arrhythmia 1.61** (1.27, 2.04) 1.16 (0.90, 1.50) 1.57** (1.31, 1.87) 0.91 (0.75, 1.10) 1.59** (1.47, 1.72) 1.01 (0.92, 1.10) 1.57** (1.47, 1.69) 0.98 (0.90, 1.06)
Parkinson's disease 4.81** (3.25, 7.12) 2.24** (1.50, 3.35) 6.45** (5.00, 8.32) 2.24** (1.72, 2.91) 6.76** (6.02, 7.59) 2.76** (2.45, 3.11) 6.94** (6.25, 7.71) 2.75** (2.47, 3.07)
These are the results of unadjusted univariate and multivariate Cox regression analysis. In adjusted analysis, all covariates listed in the table were entered into the model. No gout was the reference group for gout,
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proposed that most Alzheimer’s disease is a secondary
amyloidosis as a result of mitochondrial dysfunction. Brain
mitochondrial dysfunction leads to imbalance of aerobic
and anaerobic metabolism and triggered various cellular
responses, including tau protein phosphorylation and cell
cycle re-entry. Amyloidosis facilitates this alteration and
finally neurodegeneration happens. In addition, apolipopro-
tein E (APOE) variations may affect cholesterol transport
and affect amyloidosis [28]. APOE fragments also accu-
mulate in mitochondria and affect its function [29].
Some studies showed that uric acid might preserve mito-
chondrial function [25]. A similar neuroprotective effect
has been seen in studies of Parkinson’s disease and animal
models of multiple sclerosis [5,30,31]. For example, uric
acid is also related to repair of DNA damaged by free radi-
cals in Parkinson’s disease [30]. Hence, it is possible that
uric acid might provide a similar neuroprotective effect
against the development of Alzheimer’s disease or other
related dementia.
Vascular dementia being the second most common sub-
type of dementia accounting for 20% of all dementia was
attributable to cerebrovascular pathologies [32]. In our
study, the patients with gout also bear lower risk of devel-
oping vascular dementia, just like the observed trend in
non-vascular dementia. Though the pathogenesis of vascu-
lar dementia is different from that of Alzheimer’s disease,
they still share several common pathologic changes [33].
As in Alzheimer’s disease, amyloid angiopathy, oxidative
stress, and inflammation were involved in the pathogenesis
of vascular cognitive impairment (VCI). Deposits of Aβ in
cerebral blood vessels are associated with VCI [32]. Be-
cause of this resemblance, it is also possible that uric acid
might have neuroprotective potential in vascular dementia.
Many existing studies have shown the relationship of oxi-
dative stress and vascular dementia [32-34]. The study
done by Back et al. demonstrated that markers of oxida-
tive stress in the damaged white matter are associated with
VCI [34]. Moreover, cerebral hypoperfusion is associated
with white matter inflammation and oxidative stress in
mouse models [32]. The animal study by Dong et al. re-
vealed that administration of a superoxide scavenger in a
mouse model prevented the development of white matter
lesions and working memory deficit induced by chronic
cerebral hypoperfusion [35]. This partly proves the
concept that a superoxide scavenger might ameliorate the
development of VCI caused by vascular factors. Whether
uric acid can exert similar protection because of its scav-
enger property deserves further investigation.
In our study we noted that some patients had a history
of stroke prior to the diagnosis of Alzheimer’s disease. It is
possible that some of them actually had vascular dementia
but were misclassified as having Alzheimer’s disease.
Therefore we conducted another sensitivity analysis byreclassifying patients who had stroke prior to Alzheimer’s
disease as having vascular dementia. Then we performed
the same multivariate Cox regression test again. The re-
sults (data not shown) still revealed that patients with gout
had lower risk of developing Alzheimer’s disease and
vascular dementia.
It is also possible that the neuroprotective effect comes
from uric acid-lowering medications rather than uric acid.
To address this issue, we carried out another secondary
analysis by separating patients with gout into treated and
untreated subgroups. The definition of treated in our study
was being prescribed with any kind of uric acid-lowering
agents for more than 28 days. Patients with treated gout
still had lower risks of dementia (HR: 0.68; CI: 0.63, 0.74;
P <0.001). Those without treatment, however, did not show
significant difference in risks of dementia compared to
their controls. As our data were limited for insurance
claiming and did not provide further information on treat-
ment and test results, we could not attribute the results to
the effect of the drugs. It was possible that patients in the
untreated group had lower uric acid levels so they did not
require drugs. Alternatively, it was also possible that they
did not have gout but were misclassified. However, these
plausible explanations would not be proven in our study.
Nevertheless, from previous studies we know that drug
noncompliance and nonpersistence are common among
patients on uric acid-lowering treatment [36]. Patients with
gout in general might still have higher serum uric acid
levels. Moreover the neuroprotective effect of uric acid has
already been shown in earlier studies [8]. Therefore the dif-
ferences were more likely due to hyperuricemia itself rather
than uric acid-lowering medications.
Although our results support the hypothesis that uric
acid might have beneficial roles, such as a neuroprotective
effect, our study has some limitations. In Taiwan, most of
the citizens are not Caucasians, so whether the results of
this study represent those in other ethnic groups requires
further confirmation. In addition, all patient data are from
the insurance claim data provided by NHIRD so potential
misclassification might exist. Moreover, information on
personal lifestyle including smoking status, body weight,
body mass index, and laboratory data are not available.
However, the merits of this study are the real-world data,
large population size, and follow-up time.
Conclusions
Patients with gout tend to have lower risk of developing
dementia. Whether this effect comes from the proposed
neuroprotective effects of uric acid is not proven in our
study. However, if uric acid has neuroprotective poten-
tials, clinicians might need to reevaluate the trade-off of
reducing uric acid. Obviously, for optimal treatment of
uric acid levels, more well-designed prospective trials
are warranted.
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